Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Equity Ratio: 2009-2025

Historic Equity Ratio for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -0.36.

  • Cytokinetics' Equity Ratio fell 3644.83% to -0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -0.36, marking a year-over-year decrease of 3644.83%. This contributed to the annual value of -0.10 for FY2024, which is 79.39% up from last year.
  • Cytokinetics' Equity Ratio amounted to -0.36 in Q3 2025, which was down 20.58% from -0.30 recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Equity Ratio ranged from a high of 0.30 in Q3 2021 and a low of -0.59 during Q3 2023.
  • For the 3-year period, Cytokinetics' Equity Ratio averaged around -0.29, with its median value being -0.30 (2025).
  • As far as peak fluctuations go, Cytokinetics' Equity Ratio soared by 394.08% in 2022, and later plummeted by 3,890.04% in 2023.
  • Cytokinetics' Equity Ratio (Quarterly) stood at 0.29 in 2021, then crashed by 136.68% to -0.11 in 2022, then plummeted by 340.76% to -0.47 in 2023, then soared by 79.39% to -0.10 in 2024, then plummeted by 3,644.83% to -0.36 in 2025.
  • Its Equity Ratio stands at -0.36 for Q3 2025, versus -0.30 for Q2 2025 and -0.21 for Q1 2025.